DALLAS, Dec. 2, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to macular degeneration, today announced that Jordi Monés will provide a presentation of Nanoscope clinical data at the annual FLORetina conference taking place on December 5th-8th at the Fortezza da Basso in Florence Italy. Details for the presentation are as follows:
Session Title: Retina Futura, Session 1
Session Date: December 6th, 2024
Session Time: 12:18 pm CEST
Location: San Giovanni room, Fortezza da Basso, Florence
Presenter: Jordi Monés, MD, PhD, Director of Institut de la Màcula, and Barcelona Macula Foundation (Spain)
In addition to observed statistically significant improvements in best corrected visual acuity (BCVA) in Multi-Characteristic Opsin (MCO-010) treated retinitis pigmentosa (RP) patients of RESTORE multicenter, randomized, double-masked, sham-controlled clinical trial, Dr. Monés will present the durable efficacy and safety up to 126-week, observed in the REMAIN long term follow-up study.
About Nanoscope Therapeutics, Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for GA.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com